Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Silence Therapeutics GmbH has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are assigned to 3 distinct examiners but are all concentrated within 1 distinct art unit. This indicates a very narrow technical focus for the current pending matters, even though the examiners themselves are different for each case.
YU, DAVID TUYANG is the busiest examiner for this company, holding 1 pending office action. Since there are 3 pending office actions and 3 distinct examiners, the workload is evenly split. However, because all 3 pending office actions are in 1 distinct art unit, the examiners likely share a common technical background and follow similar art unit policies. Practitioners should note that while they are dealing with 3 distinct examiners, the single art unit environment may lead to more consistent prosecution standards than a more distributed portfolio. The 3 pending office actions represent a focused effort within the Biotechnology & Pharmaceuticals field, where the 3 distinct examiners all operate under the same specialized group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19344040 | DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF | YU, DAVID TUYANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687522 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB) IN A CELL | BRETZ, COREY LANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18745632 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | HUDSON, AMY ROSE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19344040 | DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF | YU, DAVID TUYANG | 1635 | §103 | Non-Final OA | — | Pending | Sep 29, 2025 |
| 18745632 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | HUDSON, AMY ROSE | — | §112Other | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18687522 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB) IN A CELL | BRETZ, COREY LANE | 1635 | §102§103§112Other | Non-Final OA | — | Pending | Feb 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSilence Therapeutics GmbH has 3 pending office actions as of October 2026, spread across 1 art units and 3 examiners.
David Tuyang Yu has the most, with 1 of Silence Therapeutics GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
